Leerink Partners Has Lowered Expectations for Twist Bioscience (NASDAQ:TWST) Stock Price

Key Points

• Leerink Partners lowered its price target on Twist Bioscience from $190 to $175 but kept an Outperform rating; the new target implies about 55% upside from the share price cited in the report.
• Analyst views remain mixed: MarketBeat’s consensus rating is Hold, with an average price target of $143.64.
• Twist reported quarterly revenue of $126.64 million, up 26.7% year over year and above expectations, while its $0.32-per-share loss was narrower than analysts had forecast.

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its price target dropped by research analysts at Leerink Partners from $190.00 to $175.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Leerink Partners's target price suggests a potential upside of 54.97% from the company's current price.

A number of other research analysts also recently weighed in on the company. Jefferies Financial Group started coverage on Twist Bioscience in a report on Thursday, October 8th. They set a "hold" rating and a $150.00 price target on the stock. Guggenheim lifted their target price on Twist Bioscience from $107.00 to $212.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research note on Monday, September 21st. BWS Financial reaffirmed a "sell" rating and set a $45.00 price objective on shares of Twist Bioscience in a research report on Friday, September 18th. Finally, TD Cowen reduced their price target on Twist Bioscience from $190.00 to $137.00 and set a "buy" rating for the company in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $143.64.

Twist Bioscience Trading Down 1.1%

Shares of Twist Bioscience stock traded down $1.29 on Friday, reaching $112.93. 1,582,465 shares of the company were exchanged, compared to its average volume of 1,787,548. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $219.71. The firm has a market capitalization of $7.08 billion, a price-to-earnings ratio of -50.92 and a beta of 2.25. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average price of $150.57 and a 200-day moving average price of $92.73.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. The firm had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company's revenue was up 26.7% on a year-over-year basis. On average, analysts expect that Twist Bioscience will post -2.11 EPS for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CAO Robert Werner sold 1,482 shares of the business's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $279,920.16. Following the completion of the sale, the chief accounting officer directly owned 42,917 shares of the company's stock, valued at approximately $8,106,162.96. The trade was a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 1,007 shares of the firm's stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $136,347.80. Following the completion of the transaction, the senior vice president directly owned 105,625 shares in the company, valued at $14,301,625. This trade represents a 0.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

Large investors have recently made changes to their positions in the company. Abacus Wealth Partners LLC lifted its holdings in Twist Bioscience by 4.3% during the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company's stock worth $451,000 after acquiring an additional 96 shares in the last quarter. Root Financial Partners LLC bought a new position in shares of Twist Bioscience during the 3rd quarter valued at about $33,000. GAMMA Investing LLC grew its position in shares of Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company's stock valued at $97,000 after purchasing an additional 185 shares during the period. Abel Hall LLC boosted its stake in Twist Bioscience by 3.6% in the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company's stock worth $1,066,000 after purchasing an additional 191 shares during the period. Finally, Allworth Financial LP boosted its position in shares of Twist Bioscience by 54.9% during the second quarter. Allworth Financial LP now owns 601 shares of the company's stock worth $62,000 after buying an additional 213 shares during the period.

Latest Twist Bioscience News

Here's some of the latest news about TWST:

• Positive Sentiment: Fiscal fourth-quarter revenue rose about 27% year over year to $126.6 million, beating expectations, while the $0.32-per-share loss was narrower than analyst estimates. First-quarter fiscal 2027 revenue guidance of $130 million–$132 million also topped consensus. Zacks earnings report
• Positive Sentiment: TD Cowen and Robert W. Baird maintained Buy and Outperform ratings, respectively, despite cutting their price targets to $137 and $135. Both targets imply upside from the roughly $114 reference price. TD Cowen price target update Baird price target update
• Negative Sentiment: The earnings beat did not prevent a negative market reaction: coverage pointed to an underwhelming fiscal 2027 outlook and ongoing cost pressure as concerns. The target cuts—from $190 to $137 at TD Cowen and $187 to $135 at Baird—may also weigh on sentiment, even though both firms kept positive ratings. Earnings and market reaction

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.